<br>        Inclusion criteria:<br><br>          1. Patient with a primary diagnosis of IPF (according to the 2000 American Thoracic<br>             Society/European Respiratory Society (ATS/ERS) criteria, who are willing to continue<br>             trial medication.<br><br>          2. Written informed consent signed prior to entry into the study, in accordance with<br>             International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local<br>             law<br><br>          3. Completion of 1199.30 study and still under treatment (i.e. not discontinued in parent<br>             trial)<br><br>        Exclusion criteria:<br><br>          1. Any disease that may put the patient at risk when participating in this trial.<br>             Reconsider carefully all exclusion criteria of trial 1199.30. However, patients may<br>             qualify for participation even though exclusion criteria may have been met during the<br>             course of participation in 1199.30, if the investigator's benefit-risk assessment<br>             remains favourable.<br><br>          2. Participation in another experimental clinical trial (except 1199.30) in the last 8<br>             weeks.<br><br>          3. Women who are breast feeding or of child bearing potential not using a highly<br>             effective method of birth control for at least one month prior to inclusion and at<br>             least 10 weeks after end of active therapy.<br><br>             Highly effective methods of birth control are defined as those which result in a low<br>             failure rate (i.e. less than 1 % per year) when used consistently and correctly, such<br>             as implants, injectables, combined oral contraceptives, some Intra Uterine Devices<br>             (IUDs), sexual abstinence or vasectomized partner. Female patients will be considered<br>             of childbearing potential unless surgically sterilized by hysterectomy or bilateral<br>             tubal ligation, or post-menopausal for at least two years.<br><br>          4. Sexually active males not committing to using condoms during the course of the study<br>             and at least 10 weeks after the end of active therapy (except if their partner is not<br>             of childbearing potential).<br><br>          5. Patients who require full-dose anticoagulation (e.g. vitamin K antagonists, heparin,<br>             hirudin etc).<br><br>          6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel<br>             etc) therapy.<br><br>          7. Known or suspected active alcohol or drug abuse.<br><br>          8. Patient not compliant in previous trial, with trial medication or trial visits.<br>